Home / Deep Research / Medulloblastoma

Medulloblastoma

Medulloblastoma Deep Research Fallback

⚠️ Fallback MONDO:0007959

Medulloblastoma Deep Research Fallback

Provider Attempts

No deep-research provider was invoked for this root-level entry. The two existing subgroup-specific dismech files (Medulloblastoma_WNT_Activated, Medulloblastoma_SHH_Activated) already have full deep-research artifacts in research/ from their own curation. This root entry was curated directly from the verified literature already cached in references_cache/ and shared by both subgroup files; no provider was re-run because the root scope only synthesises features that are shared across the four WHO 2021 molecular subgroups (WNT, SHH, Group 3, Group 4).

Integrated Literature Synthesis

Medulloblastoma (MONDO:0007959) is an embryonal, malignant brain tumor that arises in the cerebellum and is the most common malignant pediatric posterior-fossa tumor. PMID:35489737 ("Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions") establishes that "Recent WHO (2021) guidelines stratified MB into four molecular subgroups with four and eight further subgroups for SHH and non-WNT/non-SHH MB, respectively." The four subgroups are listed via has_subtypes rather than as a pathophysiology node — per the reviewer feedback, classification logic belongs in has_subtypes and description, not in pathophysiology[].

Cellular origin / shared mechanism. Across subgroups, tumors derive from cerebellar progenitor populations and converge on dysregulated proliferation in the developing cerebellum (CL:0001031 cerebellar granule cell, GO:0008283 cell-population proliferation INCREASED, GO:0021549 cerebellum development ABNORMAL, UBERON:0002037 cerebellum). WNT tumors derive from lower-rhombic-lip progenitors; SHH tumors from external-granule-layer granule-neuron precursors. The subgroup-specific oncogenic pathways (WNT/beta-catenin, Sonic Hedgehog, MYC-driven programs) feed this common proliferative endpoint — the single shared pathophysiology node curated here.

Clinical syndrome. Five HP-bound phenotypes are captured without frequency: tags (Headache HP:0002315, Ataxia HP:0001251, Vomiting HP:0002013, Macrocephaly HP:0000256, Papilledema HP:0001085). Per the PR review the frequency tags were removed because no quantitative cohort evidence was cited in scope to support specific frequency bands; reintroduce per the frequency-evidence SOP once subgroup-pooled clinical-cohort data are curated.

Management. Three modalities of standard care across subgroups: - Surgical resection (MAXO:0000004). - Craniospinal irradiation (MAXO:0000014), generally avoided in children <3 years to limit neurocognitive late effects. - Multi-agent chemotherapy (MAXO:0000647) with cisplatin (CHEBI:27899), vincristine (CHEBI:28445), cyclophosphamide (CHEBI:4027), and lomustine (CHEBI:6520) as the canonical agents (added in response to PR review).

Out of scope for the root entry

  • The previously-included histopathology block has been removed because it relied on NCIT:C3222 (the disease) as the finding_term and evidenced an epidemiological claim, not a pathologist-level histological finding. True histology (densely packed small blue round cells, Homer Wright rosettes, desmoplastic-nodular vs anaplastic large-cell morphology, synaptophysin expression) belongs in subgroup-specific entries and in a future repo-wide reframing of histopathology[] (the WNT and SHH subtype files carry the same "epidemiology as histopathology" pattern; flagged for follow-up).
  • Subgroup-specific driver mutations, prognosis stratification, and targeted therapy (SHH-pathway inhibitors, WNT radiation de-escalation, ONC201 for H3K27M-mutant variants) live in the existing subtype files.
  • Group 3 and Group 4 dismech entries are scoped as follow-up curation.
  • CSF biomarkers and leptomeningeal-dissemination staging biology are scoped as follow-up.